癌症干细胞标志物在甲状腺癌中的预后价值：一项系统综述。
The prognostic value of cancer stem cell markers in thyroid cancer: a systematic review.
作者信息
Peng Xingqiao, Zhu Peiye, Zhang Qiang, Li Jin
机构信息
Department of Oncology, Army Medical Center of PLA, Chongqing, China.
College of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
出版信息
Arch Med Sci. 2024 Mar 11;20(2):686-690. doi: 10.5114/aoms/185169. eCollection 2024.
INTRODUCTION
Thyroid cancer stem cells (TCSCs) play a crucial role in the pathogenesis, metastasis, and therapeutic response of thyroid cancer, making them promising biomarkers and potential targets for clinical intervention. This systematic review aims to qualitatively assess the impact of commonly used TCSC markers on the prognosis of thyroid cancer using qualitative methods.
METHODS
In total, the analysis encompassed five articles.
RESULTS
Six TCSC markers were involved, among which CD133, CD44, CD24, CD15 and ALDH1 were associated with the prognosis of thyroid cancer.
CONCLUSIONS
However, the utility of these TCSC markers in clinical practice for predicting the prognosis of thyroid cancer requires further research to provide additional evidence supporting their effectiveness.
引言
甲状腺癌干细胞（TCSCs）在甲状腺癌的发病机制、转移及治疗反应中起关键作用，使其成为有前景的生物标志物及临床干预的潜在靶点。本系统评价旨在采用定性方法定性评估常用TCSC标志物对甲状腺癌预后的影响。
方法
总共分析了5篇文章。
结果
涉及6种TCSC标志物，其中CD133、CD44、CD24、CD15和ALDH1与甲状腺癌的预后相关。
结论
然而，这些TCSC标志物在临床实践中用于预测甲状腺癌预后的效用需要进一步研究，以提供更多支持其有效性的证据。
Zotero 插件